{"type":"trials","record":{"id":41446,"source_id":"clinicaltrials-gov","external_id":"NCT07367282","title":"Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration","brief_summary":"If the subject who has nAMD voluntarily agrees to participate in this clinical study by signing the informed consent form, screening assessments will be conducted within 4 weeks prior to the first dose of the investigational drug. During the screening visit, the eligibility of the subject will be assessed and one study eye will be selected. If both eyes are eligible, the eye with the worst best-corrected visual acuity (BCVA) at screening will be chosen. However, if the investigator determines that the other eye requires more urgent treatment for clinical reasons, that eye may be selected as the study eye. After screening assessments and evaluation based on inclusion/exclusion criteria, eligible subjects will be enrolled. Vabysmo® 6 mg (0.05 mL) will be administered via intravitreal injection every 4 weeks (monthly) for a total of 4 doses during the initial loading period. After the loading dose, patients will undergo disease activity assessment based on imaging and visual acuity (VA) outcomes followed by the IP administration at Week 20. The treatment interval will be determined based on disease activity assessed at Week 20, depending on the results, the subsequent administration may be scheduled at Week 28 or Week 32, at the investigator's discretion. Thereafter, the dosing interval may be further adjusted in 4-week increments, either extended or shortened, according to imaging and visual outcomes. Throughout the clinical study, patients will need to visit the study site at least 10 times, including the screening visit. The number of intravitreal injections administered will be 4 doses during the initial loading period and up to 5 doses during the treat-and-extend (T\\&E) period (Weeks 20, 28, 36, 44, 52). Thus, the total number of injections during the study will range from a minimum of 7 to a maximum of 9 injections. If the non-study eye also has nAMD, treatment with a locally approved therapy may be administered outside the scope of this study.","overall_status":"Recruiting","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"Junyeop Lee","enrollment":64,"countries":["South Korea"],"start_date":"2026-06-29","completion_date":"2028-12-31","last_update_date":"2026-07-27","source_url":"https://clinicaltrials.gov/study/NCT07367282","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"nAMD","age_range":"50 Years","comparator":null,"organization":"Asan Medical Center","interventions":["Faricimab Injection [Vabysmo]"],"registry_source":"ClinicalTrials.gov","outcome_measures":["ANG-2 level in aqueous humour (AH) — at Week 20 from baseline","Endothelial ANG-2 level in aqueous humour (AH) — At weeks 4, 12, 20 and 52 from baseline","BCVA measurement — At weeks 20 and 52 from baseline","Subfoveal choroidal thickness — At weeks 20 and 52 from baseline","Central subfield thickness (CST) — At weeks 20 and 52 from baseline","Intraretinal microaneurysms and vessel density of the deep capillary plexus — At weeks 20 and 52 from baseline","Area of peripheral non-perfusion in the retina — At weeks 20 and 52 from baseline","High improvement in vascular stabilization — from baseline at Weeks 20","Complete polyp regression — At weeks 20 and 52 from baseline","Polyp inactivation — At weeks 20 and 52 from baseline","Resolution of central Intraretinal fluid/Subretinal fluid(IRF/SRF) — At weeks 20 and 52 from baseline","Vascular remodeling — At weeks 20 and 52 from baseline","Number of injections per patient — From baseline to Week 52(EOS)","Treatment interval — From baseline to Week 52(EOS)","Maximum treatment interval — From baseline to Week 52(EOS)"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Macular Degeneration","Faricimab Injection [Vabysmo]"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07367282","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-06-29 to 2028-12-31","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.814Z","intervention":["Faricimab Injection [Vabysmo]"],"participants":64,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["ANG-2 level in aqueous humour (AH) — at Week 20 from baseline","Endothelial ANG-2 level in aqueous humour (AH) — At weeks 4, 12, 20 and 52 from baseline","BCVA measurement — At weeks 20 and 52 from baseline","Subfoveal choroidal thickness — At weeks 20 and 52 from baseline","Central subfield thickness (CST) — At weeks 20 and 52 from baseline","Intraretinal microaneurysms and vessel density of the deep capillary plexus — At weeks 20 and 52 from baseline","Area of peripheral non-perfusion in the retina — At weeks 20 and 52 from baseline","High improvement in vascular stabilization — from baseline at Weeks 20","Complete polyp regression — At weeks 20 and 52 from baseline","Polyp inactivation — At weeks 20 and 52 from baseline","Resolution of central Intraretinal fluid/Subretinal fluid(IRF/SRF) — At weeks 20 and 52 from baseline","Vascular remodeling — At weeks 20 and 52 from baseline","Number of injections per patient — From baseline to Week 52(EOS)","Treatment interval — From baseline to Week 52(EOS)","Maximum treatment interval — From baseline to Week 52(EOS)"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41446","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}